A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan.
Taigo KatoSatoru YumibaWataru NakataKosuke NakanoAkira NagaharaKyosuke MatsuzakiYujiro HayashiKoji HatanoAtsunari KawashimaTetsuya TakaoKensaku NishimuraYasutomo NakaiMasashi NakayamaKazuo NishimuraShingo TakadaMasao TsujihataMotohide UemuraNorio NonomuraRyoichi ImamuraPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Nivolumab and axitinib showed similar clinical benefits as secondary treatment in patients with mRCC; thus, they should be an option in sequential therapy following treatment with tyrosine kinase inhibitors (TKIs). Future studies and feasible therapeutic biomarkers would help predict the clinical response to TKIs or immune checkpoint inhibitors in patients with mRCC.